Federal Register / Vol. 80, No. 11 / Friday, January 16, 2015 / Notices 2423 

1The purpose of this remedy study differs from 

the aims of other more specific, in-depth merger 

retrospectives, such as those examining hospital, 

petroleum, and grocery store mergers. 

Board of Governors of the Federal Reserve 

System, January 12, 2015. 

Michael J. Lewandowski, 

Assistant Secretary of the Board. 

[FR Doc. 2015–00559 Filed 1–15–15; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL TRADE COMMISSION 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request 

AGENCY: Federal Trade Commission 

(‘‘Commission’’ or ‘‘FTC’’). 

ACTION: Notice; request for comments. 

SUMMARY: The Commission plans to 

conduct a study to update and expand 

on the divestiture study it conducted in 

the mid-1990s to assess the effectiveness 

of the Commission’s policies and 

practices regarding remedial orders 

where the Commission has permitted a 

merger but required a divestiture or 

other remedy, and identify the factors 

that contributed to the Commission 

successfully or unsuccessfully achieving 

the remedial goals of the orders. This is 

the first of two notices required under 

the Paperwork Reduction Act (‘‘PRA’’) 

in which the Commission seeks public 

comment on its proposed study before 

requesting Office of Management and 

Budget (‘‘OMB’’) review of, and 

clearance for, the collection of 

information discussed herein. 

DATES: Comments must be received on 

or before March 17, 2015. 

ADDRESSES: Interested parties may file a 

comment online or on paper, by 

following the instructions in the 

Request for Comment part of the 

SUPPLEMENTARY INFORMATION section 

below. Write ‘‘Remedy Study, FTC File 

No. P143100’’ on your comment and file 

your comment online at https://

ftcpublic.commentworks.com/ftc/

hsr2014divestiturestudypra by following 

the instructions on the web-based form. 

If you prefer to file your comment on 

paper, write ‘‘Remedy Study, FTC File 

No. P143100’’ on your comment and on 

the envelope, and mail your comment to 

the following address: Federal Trade 

Commission, Office of the Secretary, 

600 Pennsylvania Avenue NW., Suite 

CC–5610 (Annex J), Washington, DC 

20580, or deliver your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

Constitution Center, 400 7th Street SW., 

5th Floor, Suite 5610 (Annex J), 

Washington, DC 20024. 

FOR FURTHER INFORMATION CONTACT: 

Daniel P. Ducore, Assistant Director, 

202–326–2526, Compliance Division, 

Bureau of Competition, Federal Trade 

Commission, Washington, DC 20580, or 

Timothy Deyak, Associate Director, 

202–326–3742, Bureau of Economics, 

Federal Trade Commission, 

Washington, DC 20580. 

SUPPLEMENTARY INFORMATION: 

I. Summary 

The FTC, along with the Antitrust 

Division of the Department of Justice, 

enforces the antitrust laws. Under this 

authority, the Commission examines 

consummated and proposed 

transactions to determine whether 

anticompetitive effects are likely 

because of the transaction. Each year, 

the Commission challenges a number of 

transactions. Most of those are resolved 

through a consent order providing a 

remedy to address the competitive 

concern. In horizontal mergers, the 

Commission typically requires a 

divestiture of assets to remedy the 

probable anticompetitive effects of the 

transaction. In a study that began in 

1995 and culminated with the 

publication of a report in August 1999, 

the FTC’s Bureau of Competition 

evaluated those divestitures the 

Commission ordered from FY 1990 

through FY 1994. The Commission 

refined and improved its divestiture 

orders partly as a result of that study. 

The Commission now proposes a new 

study to focus on more recent orders, 

both divestiture orders that incorporated 

modifications based on the prior study 

and orders that required remedies other 

than divestitures. 

II. Background 

In the mid-1990s, taking advantage of 

its unique research and study function, 

the Commission authorized a study of 

Commission-ordered divestitures. As 

part of that study, which was conducted 

by the Bureaus of Competition and 

Economics, Commission staff 

interviewed thirty-seven buyers out of 

the fifty that acquired assets under the 

thirty-five orders the Commission 

issued from FY 1990 through FY 1994. 

The study yielded valuable information. 

The FTC’s Bureau of Competition 

synthesized, summarized, and made 

available to the public the learning 

gained from the interviews, in a report 

the Bureau of Competition issued in 

August 1999. The report is available on 

the FTC’s Web site at http://

www.ftc.gov/sites/default/files/

attachments/merger-review/

divestiture.pdf. 

Based on the study, the Commission 

implemented several changes to its 

divestiture process. First, it shortened 

the divestiture period from a largely 

standard twelve months to six or fewer 

months. Second, recognizing the risks 

posed by divestitures of assets that 

comprised less than an on-going 

business, the Commission began more 

consistently requiring up-front buyers in 

cases in which it allowed such a 

divestiture. Third, the Commission 

began requiring monitors more 

frequently, particularly in divestitures 

in technology and pharmaceutical 

industries. These changes were 

implemented almost immediately, and 

the Commission and its staff still rely on 

the findings from the study as they craft 

and enforce the Commission’s remedies. 

The FTC has not conducted a broad 

review of its divestitures since the 

earlier study and the resulting 

modifications based on it. Accordingly, 

the Commission now proposes a new 

study to focus on more recent orders, 

many of which incorporated these 

modifications, and to include some 

orders that did not require divestitures. 

III. FTC’s Proposed Study 

A. Description of the Collection of 

Information and Proposed Use 

Since the period covered by the prior 

remedy study through 2013, the 

Commission issued 281 orders in 

merger cases. Of those, the Commission 

proposes to study all ninety-two orders 

issued from 2006 through 2012. The 

Commission chose the latter period 

because it is not so long ago that the 

parties are likely to have forgotten 

details, but it is sufficiently long to 

assess whether divestiture orders 

created new competitors and whether 

merger orders, including divestiture 

orders, achieved their remedial goals.1

The industries covered in this period 

are generally representative of those in 

the longer period from 1995 through 

2013. 

The Commission proposes to use a 

similar case study method as was used 

in the earlier study to evaluate the 

majority of the orders the Commission 

issued during this period. Staff will 

employ this approach on the fifty-three 

orders in which the Commission 

required a remedy in a variety of 

markets ranging from fishing lines, 

pipelines, and specialty metals to 

medical market research, pesticides, 

rock salt, and chemical rust inhibitors. 

The Appendix lists the fifty-three orders 

in chronological order based on the date 

first accepted by the Commission. Of the 

fifty-three merger orders the 

Commission issued during this period, 

forty-three orders required divestitures; 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
2424 Federal Register / Vol. 80, No. 11 / Friday, January 16, 2015 / Notices 

2The Commission plans to ask recipients of the 

6(b) report request to provide their annual net sales 

in dollars and units of the relevant product in the 

geographic market, for the calendar year in which 

the remedy took place and for each of the three 

calendar years before and after the remedy took 

place. If a company has fiscal year dollar and unit 

sales figures that are not calendar year sales, it will 

be asked to describe its fiscal year, provide the data 

requested for the company’s fiscal years closest to 

the calendar years requested, to estimate the 

requested calendar year dollar and unit sales, and 

to describe the basis upon which those estimates 

were made. If the requested data are not available 

for the product and the geographic market, the 

company will be asked to estimate the dollar and 

unit sales data requested and to describe the basis 

upon which its estimates were made. 

3The Commission has consistently required 

upfront buyers in supermarket cases since it 

obtained civil penalties and additional relief from 

Schnuck Markets, Inc., resulting from its failure to 

adequately maintain supermarket assets pending 

their divestiture. See FTC v. Schnuck Markets, Inc., 

No. 4:97CV01830CEJ (E.D. Mo. Sept. 16, 1997). 

under those orders, the Commission 

approved divestitures to forty-seven 

different buyers. The Commission 

proposes interviewing the forty-seven 

buyers as well as, on average, two other 

competitors, including the respondent, 

and, on average, two customers in each 

of the affected markets. For the ten 

orders in which the Commission 

ordered only non-structural relief, and 

where there are therefore no buyers, the 

Commission proposes interviewing, on 

average, two competitors, including the 

respondent, and, on average, two 

customers in each market. 

Although the FTC will seek voluntary 

interviews in the first instance, it may 

rely on compulsory process where 

necessary to obtain the information it 

needs for the study. The interviews will, 

to the extent possible, be conducted by 

attorneys and economists who are 

familiar with the order from their work 

during the time it was issued. Each 

interviewer will use similar outlines for 

the interviews, focusing broadly on the 

same topics. To the extent unique issues 

arise with respect to particular 

divestitures, the interviewer will pursue 

those issues as well. 

Although the buyer interviews will be 

similar to those in the earlier study, staff 

will focus on several specific issues, 

some of which arose from the changes 

made based on the earlier study. Those 

issues include: 

• Whether the increased use of 

buyers-up-front hindered the buyer’s 

ability to conduct adequate due 

diligence. 

• Whether shortening the divestiture 

period had any adverse effect on the 

buyers and the process. 

• To what extent the staff’s review of 

buyers and monitors may have been 

inadequate. 

• Whether the orders have effectively 

defined the assets of an autonomous 

business (when that was the purpose). 

• Whether assets outside of the 

relevant market have been properly 

included in the divestiture package 

when necessary. 

• Whether Commission orders have 

effectively required sufficient technical 

assistance or other nurturing provisions 

when necessary. 

• Whether monitors have provided 

the oversight that the Commission 

expected. 

• Whether the respondent impeded 

the buyer’s ability to compete in the 

market. 

In addition to interviewing buyers, 

the Commission will also interview 

customers and other competitors 

(including the respondent) in each 

affected market. The additional 

interviews will be used (along with the 

buyer interviews) to attempt to assess 

further whether the Commission’s 

orders achieved their remedial goals. 

These interviews will address some 

additional points, and, where 

appropriate, will cover some of the 

issues noted above. These additional 

points include: 

• Identifying the leading suppliers 

(and their market shares) of the product 

before and after the remedy. 

• Whether the buyer competed in a 

manner that was as effective as the 

previous owner of the divested assets. 

• Whether any other significant 

changes took place in the market after 

the remedy was implemented (e.g., 

entry, exit, or other merger). 

• The interviewee’s views on how the 

merger would have affected the 

competitive environment absent the 

remedy. 

• The interviewee’s views about the 

market’s competitiveness before and 

after the acquisition and remedy. 

All interviews will be conducted in a 

flexible manner, and certain specific 

questions will be explored as particular 

cases, and interview responses, indicate. 

In addition to conducting interviews, 

the FTC will require information from 

each buyer and significant competitor, 

including the respondent, in each 

market by issuing orders to file special 

reports under its authority in Section 

6(b) of the Federal Trade Commission 

Act. Information will be sought from as 

many as 280 participants. The special 

reports will request very limited annual 

unit and dollar sales data for the year 

the remedy took place, three years 

before the remedy, and three years after 

it. These data will supplement and 

complement the interview information 

for the assessment of whether the 

Commission’s orders achieved their 

remedial goals.2

The Commission proposes to use a 

different method to evaluate merger 

orders in certain other industries. The 

Commission has extensive expertise in 

crafting remedies for mergers in certain 

industries, including supermarkets, 

drug stores, funeral homes, hospitals 

and other clinics, and pharmaceuticals. 

It has implemented remedies relating to 

mergers in those industries using wellestablished methods and standard 

provisions tailored to each industry. 

Thus, for the fifteen orders the 

Commission issued from 2006 through 

2012 in which the Commission required 

over forty divestitures of supermarkets, 

drug stores, funeral homes, and 

hospitals and other clinics, also listed in 

the Appendix, the Commission does not 

propose interviewing all buyers. 

Instead, it proposes sending for 

voluntary response brief questionnaires 

to those buyers asking focused, specific 

questions that have arisen with respect 

to divestitures in those industries. For 

example, if the divested assets 

comprised a combination of assets of the 

acquiring party and of the acquired 

party, or if the divested assets 

comprised less than all of one merging 

firm’s assets in the particular market, 

did either situation disadvantage the 

firm buying the assets? Did allowing 

divestiture of a small subset of a large 

network of assets disadvantage the 

buyer in relation to a large respondent? 

Did asset deterioration issues arise in 

cases other than the supermarket cases 3

that might warrant up-front divestitures 

in those other industries? Interviews 

with all buyers are not necessary 

because repeated enforcement actions in 

each of these industries have informed 

staff’s approach to crafting subsequent 

orders. Once staff receives responses to 

the questionnaires, it will determine, on 

a case-by-case basis, whether follow-up 

phone calls with the buyers may be 

necessary. 

For the twenty-four orders that the 

Commission issued from 2006 through 

2012 requiring divestitures in the 

pharmaceutical industry, staff will 

synthesize the information the 

Commission already has; the 

Commission does not plan to interview 

the buyers of those divested assets. The 

Bureau of Competition’s Compliance 

Division maintains close contact with 

the monitors appointed in the majority 

of these orders, and the monitors and 

respondents file periodic reports as 

required by the orders. As a result, staff 

has a great deal of information on the 

status of the pharmaceutical 

divestitures, particularly with respect to 

whether the buyers have obtained 

appropriate regulatory approvals and 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 11 / Friday, January 16, 2015 / Notices 2425 

4FTC staff will give recipients of the 

questionnaires the option of responding to the 

questionnaire via telephone interview rather than 

responding in writing. Because the time and cost 

involved under either option will be similar, for 

purposes of estimating the burden, FTC staff has 

assumed written responses from the recipients. 

5The FTC will request data from all significant 

market competitors, which will include those firms 

that are interviewed (the buyer and, on average, two 

other competitors), but may include additional 

firms as well. 

6Figures based on national median salaries, 

including bonuses and benefits, divided by a 2,080 

hour work year (52 weeks × 40 hours/week), for a 

‘‘Chief Executive Officer,’’ ‘‘Top Sales & Marketing 

Executive,’’ and ‘‘Managing Attorney,’’ respectively, 

at www.salary.com. 

whether the buyers have introduced the 

product(s). Rather than attempt to 

interview all of these buyers, staff will 

collect the information it has and 

contact the monitors for follow-up 

information if necessary. Occasionally, 

follow-up phone calls with the buyers 

may be necessary; however, staff will 

decide that on a case-by-case basis. 

The Commission anticipates results 

from this study to be instructive. Partly 

in response to the prior study’s results, 

the Commission immediately 

implemented various modifications to 

its divestiture process, and it still relies 

on the learning from that study’s 

interviews to craft and enforce remedies 

today. The Commission has not 

systematically evaluated the effects of 

those changes in achieving the remedial 

goals of the orders and believes it is 

appropriate to do so now. 

B. PRA Burden Analysis 

1. Estimated Hours Burden 

a. Interviews and Questionnaires 

As described above, one component 

of the proposed study concerns fiftythree merger orders approving fortyseven buyers of divested assets. 

Commission staff will attempt to 

interview the forty-seven buyers as well 

as, on average, two customers and two 

competitors of each buyer in each 

affected market. Ten of the fifty-three 

orders required only non-structural 

relief, so there are no buyers for those 

ten; the Commission proposes to 

interview, on average, two customers 

and two competitors in each of those 

affected markets. In several of the 

orders, the relief applies to more than 

one relevant geographic or product 

market, even though there may be only 

one buyer of divested assets (or no 

buyer in the orders requiring only nonstructural relief). In other words, 

although only one buyer acquired 

assets, those assets enabled the one 

buyer to operate in more than one 

geographic market and/or more than one 

product market; there are potentially 

different customers and competitors of 

the one buyer in each of the different 

markets. There are approximately ten 

additional such markets in which there 

may be additional customers and 

competitors. Commission staff estimates 

that there will be 315 interviews [(47 

buyers) + (47 × 4 customers/

competitors) + (10 non-structural 

remedies × 4 customers/competitors) + 

(10 additional markets × 4 customers/

competitors)]. Commission staff 

anticipates that for each interview, two 

people will participate on behalf of the 

interviewee, and in many cases, an 

attorney may also participate. The 

interview will last approximately an 

hour to an hour-and-a-half. Commission 

staff estimates that an hour of 

preparation time for each interviewee 

and three hours for the attorney may be 

required. The estimated total time 

involved for three participants in this 

part of the study will thus be 2,993 

hours [315 interviews × (4.5 interview 

hours + 5 preparation time hours)]. 

As another component of the study, 

the Commission proposes sending brief 

questionnaires to the approximately 

forty buyers of divested assets under the 

fifteen orders issued from 2006 through 

2012 requiring divestiture of 

supermarkets, drug stores, funeral 

homes, and hospitals and other clinics.4

Commission staff anticipates that it will 

take an hour for the CEO or other toplevel manager and two hours for a 

marketing or sales manager to complete 

the questionnaire and then 

approximately three hours for an 

attorney to review it. The estimated total 

time involved for three participants in 

this part of the study will thus be 240 

hours [40 participants × 6 hours]. 

b. Sales Data Component 

As an additional component of this 

study, the FTC proposes obtaining and 

analyzing sales data in order to assess 

the relative health and success of 

divested entities approved in the fiftythree orders, and, to the extent possible, 

whether the order achieved its remedial 

goal. Specifically, the FTC will issue 

orders to file special reports requesting 

annual sales data (in units and dollars) 

for all significant competitors in each 

remedied market for the calendar year of 

the remedy, for each of the three 

calendar years prior to the remedy, and 

for each of the three calendar years 

following the remedy. This data can be 

derived from the data that firms collect 

as a part of their normal course of 

business, so for many, if not all, of the 

companies the limited data requested 

will not pose significant burdens for the 

relevant parties. 

While the majority of these fifty-three 

remedied matters involve only a single 

market, others implicate multiple 

geographic and product markets. As a 

result, the FTC anticipates sending 

special reports to market competitors in 

approximately seventy markets. A 

review of the study sample further 

indicates that, on average, staff will 

send special reports to four market 

competitors in each of the remedied 

markets, resulting in 280 orders to file 

special reports [70 markets x 4 

competitors/market].5 The Commission 

estimates that three people will be 

involved in the response to each special 

report—a senior finance executive, an 

accountant or financial analyst, and an 

attorney—and that the total time 

involved in responding to each report 

will be ten hours. Accordingly, the total 

amount of time involved for the 

participants in this part of the study will 

be approximately 2,800 hours [280 

special reports × 10 hours/report]. 

2. Estimated Cost Burden 

a. Interviews and Questionnaires 

The majority of costs incurred for 

each firm interviewed will be labor 

costs. Commission staff anticipates 

minimal capital or other non-labor 

costs. Staff also anticipates that toplevel managers will participate in each 

of the interviews, possibly the CEO or 

president and a marketing or sales 

manager. In many cases, the firms will 

likely request that the firm’s attorney 

also participate. Based on external wage 

data, the estimated hourly wages 6 for 

the expected participants are: 

CEO $655 

Sales/Marketing Manager $215 

Attorney $135 

The interview will take approximately 

an hour-and-a-half; the interviewees 

will spend approximately an hour to 

prepare, and the attorney will spend 

three hours preparing and reviewing. If 

all three individuals participate, for 

each firm total wages, rounded, will be 

approximately $2,783 [($655 × 2.5) + 

($215 × 2.5) + ($135 × 4.5)]. If the FTC 

staff interviews 315 different entities, 

total labor cost will be $878,645 [315 × 

$2,783]. 

Commission staff anticipates that to 

fill out the questionnaires, respondents 

will incur primarily labor costs, with 

minimal capital or other non-labor 

costs. Commission staff estimates that 

those labor costs, to complete and 

review the questionnaire, will be broken 

down as follows: one hour for the CEO, 

president, or other top-level manager; 

two hours for a marketing or sales 

manager; and up to three hours for an 

attorney to review the material. For each 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
2426 Federal Register / Vol. 80, No. 11 / Friday, January 16, 2015 / Notices 

7Figures based on national median salaries, 

including bonuses and benefits, divided by a 2,080 

hour work year (52 weeks × 40 hours/week), for a 

‘‘Financial Reporting Manager’’ and ‘‘Lead 

Accountant,’’ respectively, at www.salary.com. See 

also supra note 6 (attorney salary source data). 

8 In particular, the written request for confidential 

treatment that accompanies the comment must 

include the factual and legal basis for the request, 

and must identify the specific portions of the 

comment to be withheld from the public record. See 

FTC Rule 4.9(c), 16 CFR 4.9(c). 

firm, total wages will be $1,490 [$655 + 

($215 × 2) + ($135 × 3)]. Staff anticipates 

obtaining completed questionnaires 

from the approximately forty buyers, for 

an associated labor cost total of $59,600 

[40 × $1,490]. 

b. Sales Data Component 

As was the case above, the majority of 

the costs incurred for compliance with 

the special reports will be labor costs. 

The Commission anticipates that a toplevel financial manager, an accountant 

or financial analyst, and an attorney will 

be involved in any discussions relating 

to the special reports and in responding 

to the special reports. Specifically, it is 

expected that each of these individuals 

would be involved in a two-hour 

discussion with Commission staff prior 

to compliance, and that the financial 

analyst would require four hours to 

compile the data. Based on external 

wage data, the estimated hourly wages 

for the expected participants are: 7

Financial Manager $75 

Accountant $55 

Attorney $135 

Total wage costs for each special 

report will be $750 [($75 × 2) + ($135 

× 2) + ($55 × 6)]. If the Commission 

issues 280 special reports, the total cost 

of complying with compulsory process 

will be $210,000 [280 × $750]. 

IV. Confidentiality 

Some of the information the 

Commission will receive in connection 

with the study is information of a 

confidential nature. Under Section 6(f) 

of the FTC Act, such information is 

protected from public disclosure for as 

long as it qualifies as a trade secret or 

confidential commercial or financial 

information. 15 U.S.C. 46(f). Material 

protected by Section 6(f) also would be 

exempt from disclosure under the 

Freedom of Information Act, 5 U.S.C. 

552. Moreover, under Section 21(c) of 

the FTC Act, a submitter who designates 

information as confidential is entitled to 

10 days’ advance notice of any 

anticipated public disclosure by the 

Commission, assuming that the 

Commission has determined that the 

information does not, in fact, constitute 

Section 6(f) material. 15 U.S.C. 57b–2(c). 

Although materials covered by these 

sections are protected by stringent 

confidentiality constraints, the FTC Act 

and the Commission’s rules authorize 

disclosure in limited circumstances 

(e.g., official requests by Congress, 

requests from other agencies for law 

enforcement purposes, administrative or 

judicial proceedings). Even in those 

limited contexts, however, the 

Commission’s rules may afford 

protections to the submitter, such as 

advance notice to seek a protective 

order prior to disclosure in an 

administrative or judicial proceeding. 

See 15 U.S.C. 57b–2(c); 16 CFR 4.9– 

4.11. 

V. Request for Comment 

Under the PRA, 44 U.S.C. 3501–3521, 

federal agencies must obtain approval 

from OMB for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ means 

agency requests or requirements that 

members of the public submit reports, 

keep records, or provide information to 

a third party. 44 U.S.C. 3502(3); 5 CFR 

1320.3(c). As required by section 

3506(c)(2)(A) of the PRA, the FTC is 

providing this opportunity for public 

comment before requesting that OMB 

approve the collection of information 

for the study. 

Pursuant to Section 3506(c)(2)(A) of 

the PRA, the FTC invites comments on: 

(1) Whether participation in the study is 

necessary, including whether the 

information will be practically useful; 

(2) the accuracy of our burden estimates, 

including whether the methodology and 

assumptions used are valid; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) ways to minimize the burden of the 

collection of information. 

You can file a comment online or on 

paper. For the Commission to consider 

your comment, we must receive it on or 

before March 17, 2015. Write ‘‘Remedy 

Study, P143100’’ on your comment. 

Your comment—including your name 

and your state—will be placed on the 

public record of this proceeding, 

including, to the extent practicable, on 

the public Commission Web site, at 

http://www.ftc.gov/os/

publiccomments.shtm. As a matter of 

discretion, the Commission tries to 

remove individuals’ home contact 

information from comments before 

placing them on the Commission Web 

site. 

Because your comment will be made 

public, you are solely responsible for 

making sure that your comment does 

not include any sensitive personal 

information, like anyone’s Social 

Security number, date of birth, driver’s 

license number or other state 

identification number or foreign country 

equivalent, passport number, financial 

account number, or credit or debit card 

number. You are also solely responsible 

for making sure that your comment does 

not include any sensitive health 

information, like medical records or 

other individually identifiable health 

information. In addition, do not include 

any ‘‘[t]rade secret or any commercial or 

financial information which is . . . 

privileged or confidential,’’ as discussed 

in Section 6(f) of the FTC Act, 15 U.S.C. 

46(f), and FTC Rule 4.10(a)(2), 16 CFR 

4.10(a)(2). In particular, do not include 

competitively sensitive information 

such as costs, sales statistics, 

inventories, formulas, patterns, devices, 

manufacturing processes, or customer 

names. 

If you want the Commission to give 

your comment confidential treatment, 

you must file it in paper form, with a 

request for confidential treatment, and 

you must follow the procedure 

explained in FTC Rule 4.9(c), 16 CFR 

4.9(c).8 Your comment will be kept 

confidential only if the FTC General 

Counsel grants your request in 

accordance with the law and the public 

interest. 

Postal mail addressed to the 

Commission is subject to delay due to 

heightened security screening. As a 

result, we encourage you to submit your 

comments online. To make sure that the 

Commission considers your online 

comment, you must file it at https://

ftcpublic.commentworks.com/ftc/

hsr2014divestiturestudypra, by 

following the instructions on the webbased form. If this Notice appears at 

http://www.regulations.gov/#!home, you 

also may file a comment through that 

Web site. 

If you file your comment on paper, 

write ‘‘Remedy Study, P143100’’ on 

your comment and on the envelope, and 

mail it to the following address: Federal 

Trade Commission, Office of the 

Secretary, 600 Pennsylvania Avenue 

NW., Suite CC–5610 (Annex J), 

Washington, DC 20580, or deliver your 

comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, Constitution Center, 400 7th 

Street SW., 5th Floor, Suite 5610 

(Annex J), Washington, DC 20024. If 

possible, submit your paper comment to 

the Commission by courier or overnight 

service. 

Visit the Commission Web site at 

http://www.ftc.gov to read this Notice 

and the news release describing it. The 

FTC Act and other laws that the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 11 / Friday, January 16, 2015 / Notices 2427 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before March 17, 2015. For information 

on the Commission’s privacy policy, 

including routine uses permitted by the 

Privacy Act, see http://www.ftc.gov/ftc/ 

privacy.htm. 

Appendix 

Date first accepted by the commission Docket No. Matter name 

Interviews 

1. 04/20/06 ................................................ C 4164 Boston Scientific Corp/Guidant Corp. 

2. 07/07/06 ................................................ C 4165 Hologic, Inc./Fischer Imaging. 

3. 07/18/06 ................................................ C 4163 Linde/BOC. 

4. 08/18/06 ................................................ C 4173 EPCO/TEPPCO. 

5. 10/03/06 ................................................ C 4188 The Boeing Company/Lockheed Martin Corp. 

6. 10/17/06 ................................................ C 4170 Thermo Electron/Fisher Scientific. 

7. 12/28/06 ................................................ C 4181 General Dynamics OTS. 

8. 01/25/07 ................................................ C 4183 Kinder Morgan inc. 

9. 08/09/07 ................................................ C 4196 Jarden Corporation/K2, Inc. 

10. 09/15/07 .............................................. C 4202 Fresenius AG/American Renal Association. 

11. 10/09/07 .............................................. C 4201 Kyphon, Inc/Disc-o-tech. 

12. 10/26/07 .............................................. C 4210 Compagnie de Saint-Gobain/Owens Corning. 

13. 04/28/08 .............................................. C 4228 Talx Corporation. 

14. 05/05/08 .............................................. C 4219 Agrium Inc./UAP Holding Corporation. 

15. 06/30/08 .............................................. C 4233 Carlyle Partners/JP Morgan. 

16. 07/10/08 .............................................. C 4231 Flow International Corporation/Omax Corp. 

17. 07/17/08 .............................................. C 4224 Pernod Ricard/V&S Spirits. 

18. 07/30/08 .............................................. C 4225 McCormick & Company/Unilever Group. 

19. 09/15/08 .............................................. C 4236 Fresenius SE/Daiichi Sankyo. 

20. 09/16/08 .............................................. C 4257 Reed Elsevier PLC/ChoicePoint Inc. 

21. 12/23/08 .............................................. C 4244 Inverness Medical Innovations, Inc./ACON. 

22. 01/23/09 .............................................. C 4243 Dow Chemical/Rohm & Haas. 

23. 01/29/09 .............................................. C 4251 Getinge AB/Datascope Corp. 

24. 02/26/09 .............................................. C 4254 Lubrizol/Lockhart Chemical. 

25. 04/02/09 .............................................. C 4253 BASF/Ciba Specialty Chemicals. 

26. 09/25/09 .............................................. C 4273 K&S AG/Dow Chemical. 

27. 11/24/09 .............................................. C 4274 Panasonic/Sanyo. 

28. 01/27/10 .............................................. C 4283 Danaher Corp/MDS. 

29. 02/26/10 .............................................. C 4301 PepsiCo Inc./Pepsi Bottling. 

30. 05/07/10 .............................................. D 9342 MDR (The Dun & Bradstreet Corp)/QED. 

31. 05/14/10 .............................................. C 4292 Varian, Inc./Agilent, Inc. 

32. 06/30/10 .............................................. C 4293 Pilot/Flying J. 

33. 07/14/10 .............................................. C 4297 AEA Investors/Wilh.Werhahn. 

34. 07/16/10 .............................................. C 4300 Fidelity/LandAmerica. 

35. 07/28/10 .............................................. C 4298 NuFarm/A.H. Marks Holdings, Ltd. 

36. 09/10/10 .............................................. C 4299 Airgas/Air Products and Chemicals. 

37. 09/27/10 .............................................. C 4305 Coca-Cola/Coca-Cola Enterprise. 

38. 10/11/10 .............................................. C 4307 Simon Property Group/Prime Outlets. 

39. 12/29/10 .............................................. C 4314 Keystone/Compagnie de Saint-Gobain. 

40. 05/26/11 .............................................. C 4328 Irving/Exxon Mobil. 

41. 10/28/11 .............................................. C 4340 IMS Health/SDI Health. 

42. 12/08/11 .............................................. C 4341 LabCorp/Orchid Cellmark. 

43. 01/11/12 .............................................. C 4346 Amerigas/ETP. 

44. 02/29/12 .............................................. C 4349 Carpenter/HHEP-Latrobe. 

45. 03/05/12 .............................................. C 4350 Western Digital/Hitachi. 

46. 04/26/12 .............................................. C 4368 CoStar/Loopnet. 

47. 05/01/12 .............................................. C 4355 Kinder Morgan/El Paso. 

48. 06/11/12 .............................................. C 4363 Johnson & Johnson/Synthes. 

49. 08/06/12 .............................................. C 4366 Renown Health/Reno Heart Physicians. 

50. 10/12/12 .............................................. C 4381 Magnesium Elektron. 

51. 10/31/12 .............................................. C 4380 Corning, Inc. 

52. 11/15/12 .............................................. C 4376 Hertz Global Holdings. 

53. 11/26/12 .............................................. C 4377 Robert Bosch. 

Questionnaires 

Supermarkets and drug stores 

1. 06/04/07 ................................................ C 4191 Rite Aid/Eckerd. 

2. 06/05/07 ................................................ D 9324 Whole Foods. 

3. 11/27/07 ................................................ C 4209 A&P/Pathmark. 

4. 08/04/10 ................................................ C 4295 Topps. 

5. 06/15/12 ................................................ C 4367 Giant/Safeway. 

Funeral homes 

6. 11/22/06 ................................................ C 4174 SCI/Alderwoods. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
2428 Federal Register / Vol. 80, No. 11 / Friday, January 16, 2015 / Notices 

Date first accepted by the commission Docket No. Matter name 

7. 11/24/09 ................................................ C 4275 SCI/Palm. 

8. 3/25/10 .................................................. C 4284 SCI/Keystone. 

Hospitals and other clinics 

9. 03/30/06 ................................................ C 4159 Fresenius AG. 

10. 10/07/09 .............................................. D 9338 Carilion Clinic. 

11. 11/25/10 .............................................. C 4309 Universal/PSI. 

12. 07/21/11 .............................................. C 4339 Cardinal/Biotech. 

13. 09/02/11 .............................................. C 4334 Davita/DSI. 

14. 02/28/12 .............................................. C 4348 Fresenius AG. 

15. 10/5/12 ................................................ C 4372 Universal/Ascend. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 2015–00666 Filed 1–15–15; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Advisory Council on Alzheimer’s 

Research, Care, and Services; Meeting 

AGENCY: Assistant Secretary for 

Planning and Evaluation, HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces the 

public meeting of the Advisory Council 

on Alzheimer’s Research, Care, and 

Services (Advisory Council). The 

Advisory Council on Alzheimer’s 

Research, Care, and Services provides 

advice on how to prevent or reduce the 

burden of Alzheimer’s disease and 

related dementias on people with the 

disease and their caregivers. During the 

January meeting, the Advisory Council 

will hear a presentation on IOM’s final 

expert panel on Advanced Dementia, 

which will provide additional 

recommendations for the Council to 

consider. The Advisory Council will 

spend the majority of the meeting 

considering recommendations made by 

each of the three subcommittees for 

updates to the 2015 National Plan. 

DATES: The meeting will be held on 

January 26th, 2014 from 9 a.m. to 5 p.m. 

EDT. 

ADDRESSES: The meeting will be held in 

the Great Hall in the Hubert H. 

Humphrey Building, 200 Independence 

Avenue SW., Washington, DC 20201. 

Comments: Time is allocated midmorning on the agenda to hear public 

comments. The time for oral comments 

will be limited to two (2) minutes per 

individual. In lieu of oral comments, 

formal written comments may be 

submitted for the record to Rohini 

Khillan, OASPE, 200 Independence 

Avenue SW., Room 424E, Washington, 

DC 20201. Comments may also be sent 

to napa@hhs.gov. Those submitting 

written comments should identify 

themselves and any relevant 

organizational affiliations. 

FOR FURTHER INFORMATION CONTACT: 

Rohini Khillan (202) 690–5932, 

rohini.khillan@hhs.gov. Note: Seating 

may be limited. Those wishing to attend 

the meeting must send an email to 

napa@hhs.gov and put ‘‘January 26 

Meeting Attendance’’ in the Subject line 

by Friday, January 16, so that their 

names may be put on a list of expected 

attendees and forwarded to the security 

officers at the Department of Health and 

Human Services. Any interested 

member of the public who is a non-U.S. 

citizen should include this information 

at the time of registration to ensure that 

the appropriate security procedure to 

gain entry to the building is carried out. 

Although the meeting is open to the 

public, procedures governing security 

and the entrance to Federal buildings 

may change without notice. If you wish 

to make a public comment, you must 

note that within your email. 

SUPPLEMENTARY INFORMATION: Notice of 

these meetings is given under the 

Federal Advisory Committee Act (5 

U.S.C. App. 2, section 10(a)(1) and 

(a)(2)). Topics of the Meeting: The 

Advisory Council will hear 

presentations on the basics of long-term 

care, including presentations on 

programs, settings, and payers. The 

Council will use a portion of the 

meeting to review the work it has 

accomplished thus far towards the 2025 

goals, and then discuss the process for 

developing recommendations for the 

2015 update to the National Plan. The 

Council will also hear presentations 

from the three subcommittees (Research, 

Clinical Care, Long-Term Services and 

Supports, and Ethics). 

Procedure and Agenda: This meeting 

is open to the public. Please allow 30 

minutes to go through security and walk 

to the meeting room. The meeting will 

also be webcast at www.hhs.gov/live. 

Authority: 42 U.S.C. 11225; Section 2(e)(3) 

of the National Alzheimer’s Project Act. The 

panel is governed by provisions of Public 

Law 92–463, as amended (5 U.S.C. Appendix 

2), which sets forth standards for the 

formation and use of advisory committees. 

Dated: January 5, 2015. 

Richard G. Frank, 

Assistant Secretary for Planning and 

Evaluation. 

[FR Doc. 2015–00517 Filed 1–15–15; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–15–14AYC] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 


asabaliauskas on DSK5VPTVN1PROD with NOTICES